Comparative Study Shows Differences Between Letrozole and Tamoxifen on Breast Cancer Recurrence Risk

The results from a recent clinical trial conducted by the Breast International Group show that Novartis' breast cancer treatment Femara (active ingredient: letrozole) provides better post-surgery protection against breast cancer recurrence than tamoxifen, the current primary therapy.

According to clinical data presented at the Primary Therapy of Early Breast Cancer 9th International Confere...